BioSpace News Archive

In a notice received today by TaiMed from the FDA, the Prescription Drug User Fee Act (“PDUFA”) target action date has been extended to April 3, 2018.

DelMar exec management will host a business update conference call and live webcast for investors, analysts and other interested parties on Tuesday, November 14, 2017 at 4:30 p.m. Eastern Standard Time.

Alnylam announced the pricing of an underwritten registered public offering of 5,600,000 shares of its common stock at a public offering price of $125.00 per share.

In vitro and in vivo preclinical models demonstrate eFT508 selectively downregulates key immune checkpoint proteins without compromising T cell activation or viability.

Management will hold a conference call to provide a business update and host a discussion on recent and upcoming milestones.

Data show mean improvement demonstrated at one year post one-time administration maintained through at least three years for original intervention cohort, and two years for crossover cohort, with observation ongoing.

The presentation is focused primarily upon immunology data from the ADAPT clinical trial and includes both new data and an update to data that was previously presented at the European Society of Medical Oncology Conference in September.

Calyxt will host an investor call on November 14, 2017 at 8:00am Eastern Time to discuss its financial results and provide a general business update.

This research, which was conducted at Wilmer Eye Institute at Johns Hopkins University, Stanford University, and the University of California, San Francisco, appears to reaffirm earlier research that showed a higher lifetime exposure to estrogen is linked to a lower risk of developing glaucoma, suggesting a possible new preventative treatment path.

Net loss for the quarter ended September 30, 2017 was $4.5 million or $0.31 loss per share, compared to a net loss of $2.3 million or $0.22 loss per share for the quarter ended August 31, 2016.